在中式养生新潮流下，"药食同源"越来越成为广大消费者认同的消费理念。近期，乳业龙头伊利与同仁 堂（600085）达成全面战略合作。双方强强联合，以现代智造赋能传统智慧，打造更适合国民体质的营 养健康新供给。 两大巨头合作的核心驱动力，直指中国健康消费市场的结构性变革。 从"脆皮"年轻人"熬最深的夜，吃最贵的保健品"式的"朋克养生"热，到中老年群体围绕慢性病预防兴起 的食疗滋补风潮，国民健康意识大幅提升，带动健康食品消费需求持续增长。受益于本土中医药文化影 响，"药食同源"理念愈发深入人心。 伊利与同仁堂的跨界融合，正是基于对"药食同源"理念的创新实践，双方以"精准营养"为核心，通过一 系列更高品质的精准营养解决方案，深度满足了消费者不断升级的健康需求。 高品质追求 书写大健康产业新叙事 在这场跨界合作中，"品质"是最核心的关键词之一。"伊利即品质，视品质如生命"是伊利集团的企业信 条，也恰恰与同仁堂对品质的坚守不谋而合。市场环境风云变幻，消费者和投资者越来越看重品质，而 品质才是伊利的最强护城河。一个企业难以被别人短时间复制的能力，就是一个企业的最强护城河。品 质打造不是一日之功，是公司在多年发展中，方方面面 ...

证券代码：600085 证券简称：同仁堂 公告编号：2025-009 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 为贯彻落实国家关于大力开展国潮出海业务战略部署，助力中医药文化全球传播， 北京同仁堂股份有限公司（以下简称公司或本公司）控股孙公司北京同仁堂国药有限 公司（以下简称同仁堂国药）与中免国际有限公司（以下简称中免国际）签订了《战 略合作协议》（以下简称本协议），本协议仅为合作意向性协议，后续双方将根据实际 需要签署具体合作协议以明确合作事宜并深化双方合作。具体情况如下： 一、 本协议签订的基本情况 (一) 交易对方的基本情况 公司名称：中免国际有限公司 地 址：中国香港湾仔告士打道108号光大中心16层 商业登记号：20392459 股东情况：中国旅游集团中免股份有限公司（股票代码为601888.SH）全资子公 司中免集团（海南）运营总部有限公司持股100%。 北京同仁堂股份有限公司 关于控股孙公司签订战略合作协议的公告 资产总额为人民币2,629,991.97万元，净资产为人民币2,100,392 ...

智通财经4月8日电，中国中免(601888.SH)公告称，中国旅游集团中免股份有限公司全资子公司中免国 际有限公司与北京同仁堂国药有限公司签订了《战略合作协议》，旨在通过合作实现共同发展、利益最 大化。合作内容包括扩大国内、海外渠道及产品合作范围，探索同仁堂活络油、中式抗衰老系列等产品 于中免渠道专供版本的合作，以及中式养生餐饮类创新业态合作。本协议为意向性协议，对公司2025年 度经营业绩不会构成重大影响，具体合作事宜和实施内容尚存在不确定性。 中国中免：全资子公司与北京同仁堂国药有限公司签订战略合作协议 ...

Core Viewpoint - Beijing Tongrentang Co., Ltd. has developed a "Smart Visualization Platform" to enhance data utilization for high-quality development, receiving software copyright certification from the National Copyright Administration [1][2] Group 1: Platform Development and Features - The Smart Visualization Platform is a business intelligence management tool based on big data and artificial intelligence, transforming complex marketing data into intuitive graphics and reports [1] - The platform aims to improve decision-making accuracy and address challenges faced during the company's development process [1] - It has been widely applied in sales management, inventory monitoring, and channel optimization, significantly enhancing the effectiveness of marketing management [1] Group 2: Marketing Strategy and Risk Management - The platform analyzes data to refine marketing processes and develop customized reports, supporting the company's diverse management needs [2] - It features real-time alerts, risk control, and intelligent analysis, establishing a comprehensive risk prevention system that can quickly identify potential risks and issue warnings [2] - Over 2,200 commercial or terminal entities have successfully integrated the platform, greatly improving work efficiency and breaking down data silos for multidimensional data integration and analysis [2]

同仁堂商业下属零售药店主要开设在全国重点城市和地区，并逐步向周边发展，以线下直接服务客户群体为主，主要 销售中西成药及饮片、保健品及食品、医疗器械等。根据药店所处地区消费水平、消费特点，零售药店调整和丰富产 品结构，满足消费者的差异化需求。 报告期内，零售药店通过销售中西成药及饮片获得的销售收入占零售总收入的 81.87%，其次为保健品及食品。零售药 店在 2024 年从前 5 名供应商处采购中西成药及饮片，共计约 48.45 亿元，较上年同期增加 21.89%。零售药店中，有 720 家设立了中医医疗诊所，占零售药店总数 57.55%；有 809 家取得"医疗保险定点零售药店"资格，占公司零售药店 总数 64.67%。 近日，同仁堂发布2024年财报。披露公司去年营收增长4.12%至185.97亿元，归属净利减少8.54%至15.26亿元。 截至报告期末，同仁堂商业共设立零售门店 1,251 家，2024 年内新增门店数量 250 家，其中新设 252 家，闭店 2 家。 主要地区变动情况如下：公司零售总部地处华北地区核心地带，品牌及公司文化对周边地区影响力较强，报告期内新 增店铺 97 家，年底达到 51 ...

老字号企业北京同仁堂股份有限公司（以下简称"同仁堂"，股票代码600085.SH）营收净利背离。 长江商报消息 ●长江商报记者 沈右荣 4月3日晚，同仁堂披露了2024年年报。公司实现营业收入约186亿元，同比增长逾4%；归属母公司股东的净利润 （简称"归母净利润"）逾15亿元，同比下降近9%。其中，第四季度，营业收入增长超过15%，而归母净利润下降 幅度接近37%。 归母净利润下降，这是2020年以来的首次。 同仁堂主要从事中成药的生产与销售，拥有完整的产业链条。 对于2024年归母净利润下降，公司解释称，主要是中药材价格上涨使产品成本增加。 与之对应的是，公司综合毛利率、净利率均较上年有所下降。 不缺钱的同仁堂大幅提高分红比例。2024年全年，公司将合计派发现金红利13.71亿元，较2023年翻了一倍，分红 率接近90%。 根据长江商报记者粗略测算，2024年，同仁堂的员工平均薪酬约19.99万元，较上年下降约2.37%。而包括总经理 在内的9名董监高，薪酬均有明显上涨。 时隔四年净利润再现下降 时隔四年，同仁堂的归母净利润再度出现下降。 根据年报，2024年，同仁堂实现营业收入185.97亿元，同比增长 ...

Group 1 - The company plans to distribute a cash dividend of 5.00 yuan (including tax) for every 10 shares, amounting to a total of 1,371,470,262.00 yuan, which represents 44.93% of the net profit attributable to the parent company for the year 2024 [12][13][68] - The company achieved a net profit of 1,526,274,925.98 yuan for the year 2024, with a total revenue of 1,859,728.16 yuan, reflecting a year-on-year growth of 4.12% [6][7][12] - The total assets of the company reached 3,119,752.40 million yuan, an increase of 3.68% year-on-year, while the net assets attributable to shareholders grew by 1.06% [7][12] Group 2 - The company operates in the traditional Chinese medicine sector, focusing on the production and sales of traditional Chinese medicine products, with over 400 varieties in its portfolio [3][5][6] - The company is committed to high-quality development and has implemented strategies to enhance production efficiency and investor returns [6][27][30] - The regulatory environment for traditional Chinese medicine is evolving, with new standards and guidelines being introduced to promote quality and innovation in the industry [4][5][6] Group 3 - The company has a complete industrial chain that includes planting, processing, research and development, production, logistics, and retail of traditional Chinese medicine [5][6] - The company has received approval for its profit distribution plan from the board of directors and the supervisory board, pending shareholder approval [12][54][71] - The company has engaged Zhongshun Zhonghuan Accounting Firm for auditing services, with a proposed fee of 2.56 million yuan for the 2025 fiscal year [80][89][91]

Core Insights - Tongrentang reported a revenue of 18.597 billion yuan for 2024, a year-on-year increase of 4.12%, while net profit attributable to shareholders decreased by 8.54% to 1.526 billion yuan [1] - The company experienced significant growth in its core business, particularly in cardiovascular products and tonics, with revenues of 5.146 billion yuan and 2.127 billion yuan respectively, reflecting year-on-year increases of 17.26% and 22.98% [1] - The company has increased its self-operated pharmacy count by 250 to a total of 1,251, showing a notable improvement compared to previous years [1] Financial Performance - In Q4 2024, Tongrentang achieved a revenue of 4.778 billion yuan, a year-on-year increase of 15.41%, but net profit fell by 36.65% to 176 million yuan [1] - The company's gross margin for cardiovascular products decreased by 8.31 percentage points to 49.31%, marking the first time it has fallen below 50% in five years, primarily due to rising raw material costs [2] - The company plans to increase cash dividends to 1.371 billion yuan, representing 89.86% of the net profit attributable to shareholders, indicating a commitment to shareholder returns despite declining profits [3] Future Outlook - The gross margin pressure is expected to improve by 2025 due to potential cost relief from imported raw materials and possible price adjustments for key products [2] - The company maintains a "buy" rating, with projected net profits of 1.815 billion yuan, 2.102 billion yuan, and 2.429 billion yuan for 2025-2027, reflecting year-on-year growth rates of 18.90%, 15.84%, and 15.55% respectively [3]

Group 1 - Fudan University Zhongshan Hospital has developed a bile duct cancer precision testing kit that has received approval from the Shanghai Municipal Drug Administration, achieving an 86% increase in overall detection rate and reducing average testing time from 17.6 days to 5 days [1] - Jianyou Co., Ltd. announced that its liraglutide injection has received FDA approval, which may enhance its competitiveness and brand influence in the international market [2] - Jiangsu Lifeng Biotechnology was fined a total of 37.73 million yuan for falsifying registration documents for medical devices, highlighting the regulatory body's zero-tolerance policy towards fraud [3] Group 2 - Tongrentang reported a 4.12% increase in total operating revenue for 2024, reaching 18.597 billion yuan, but its net profit decreased by 8.54% to 1.526 billion yuan, attributed to rising raw material costs and imbalances in marketing and R&D investments [4]

Industry Overview - Chinese herbal medicine is a unique drug used in traditional Chinese medicine for disease prevention and treatment, encompassing both herbal medicine and traditional Chinese drugs [1][5] - The market size of Chinese herbal medicine planting in China is projected to grow from 156.3 billion yuan in 2019 to 295.68 billion yuan in 2024, with a year-on-year growth rate of 30.2% [9] - The planting area for Chinese herbal medicine has increased from 52.5 million mu in 2019 to 59.56 million mu in 2024, reflecting a year-on-year growth rate of 5.87% [5][9] Industry Chain - The upstream of the industry chain includes the planting of Chinese herbal medicine, breeding of medicinal animals, and collection of raw materials, with key players such as Baiyunshan, Kangmei Pharmaceutical, and Yunnan Baiyao [2] - The midstream involves the processing and manufacturing of Chinese herbal products, including traditional Chinese medicine and herbal pieces, with companies like Kangmei Pharmaceutical and Huaren Sanjiu leading this segment [2] - The downstream focuses on the distribution and sales of Chinese herbal products through traditional pharmacies and e-commerce platforms [2] Market Dynamics - The demand for Chinese herbal medicine is increasing due to factors such as industrialization, urbanization, and an aging population, alongside supportive government policies [9] - The recognition of traditional Chinese medicine in international markets is also on the rise, contributing to the industry's rapid growth [9] Competitive Landscape - The competitive landscape of the Chinese herbal medicine planting industry is tiered based on registered capital, with the first tier exceeding 1 billion yuan, including companies like Yunnan Baiyao and Kunming Pharmaceutical [11][13] - The second tier has registered capital between 500 million to 1 billion yuan, featuring companies like Yibai Pharmaceutical and Dong'e Ejiao [11][13] - The third tier consists of companies with registered capital below 500 million yuan, such as Foci Pharmaceutical and Zhendong Pharmaceutical [11][13] Development Trends - The establishment of geographical indication and ecological planting models is accelerating the construction of authentic medicinal material protection zones [17] - The standardization of seeds and seedlings is expected to overcome industry bottlenecks, with significant improvements in the coverage of quality seeds [17] - International certifications such as EU organic certification and US NOP standards are becoming essential for export enterprises, enhancing the competitiveness of Chinese herbal products in global markets [18]